Kornimate/medical-research-clean huggingface dataset:
evaluating pharmacogenomic variants for cardiology therapeutics

Conditions: Thrombosis; Stent Thrombosis; Bleeding; Myocardial Infarction; Ischemic Stroke

Summary: cipherome's lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.

the lighthouse tool incorporates pharmacogenetic (pgx) variants from well-established, evidence-based guidelines to provide personalized drug response profile(s) to guide treatment decisions. the patient specimen is genotyped using a proprietary, carefully curated pharmacogenetic variant panel to determine the individual's phenotype. the lighthouse report (pgx findings) are provided to the clinician, and a notification is generated when the patient has a genotype with a deleterious drug-metabolizing phenotype. evaluating the south texas community for the pilot project will enhance the understanding of the impact of genetic variants on individuals of hispanic/latino ancestry, especially as the variants pertain to the efficacy and safety of medications.

Eligibility criteria:
inclusion criteria: * subjects over 18 years of age, who are: * on clopidogrel, prasugrel or ticagrelor after percutaneous stent * completed informed consent exclusion criteria: * failure to provide informed consent. * lost to follow-up prior to 60 days.

Keywords: stent thrombosis major adverse cardiovascular and cerebrovascular events (macce)
cohort study of inpatients and outpatient patients with cerebral small vessel disease

Conditions: Cerebral Small Vessel Diseases

Summary: this cohort study involves the dynamic collection of clinical information, including serum parameters , blood pressure variability, imaging data, and neuropsychological scales, in patients with cerebral small vessel disease (csvd). the study aims to summarise the clinical and imaging characteristics of the csvd population and identify novel csvd risk factors. additionally, this study intend to uncover the mechanisms underlying the clinical and imaging outcomes of csvd. furthermore, a multivariable prediction model for cognitive and mood disorders in patients with csvd will be established.

research objectives: 1. to conduct a longitudinal study on patients with cerebral small vessel disease (csvd) and observe the dynamic evolution of their cognitive functioning, emotional disorders, and other related factors. 2. to explore and summarize the clinical and radiological characteristics of the csvd population, and identify new risk factors for csvd. 3. to investigate in depth the underlying mechanisms and the relationship between clinical and radiological outcomes in csvd. 4. to establish a multifactor prediction model for cognitive and emotional disorders in csvd.

Eligibility criteria:
inclusion criteria: 1. participants aged between 18 and 80 years, with no restriction on gender. 2. participants who have completed a 3.0t mri of the head within one year at yueyang hospital, and meet the imaging diagnostic criteria of the 2013 strive guidelines. 3. participants who have a modified rankin scale (mrs) score of 0-2 (able to perform activities of daily living) at the time of the visit. 4. participants who are able to understand and agree to participate in the study, and have signed the informed consent form. exclusion criteria: 1. diagnosis of symptomatic lacunar syndrome without 6 months of onset (participants can be enrolled after 6 months to avoid the impact of the acute phase). 2. intracranial and extracranial vascular examination confirms stenosis of the blood vessel by ≥50%. 3. imaging data reveals intracranial space-occupying lesions. 4. a history of other neurological or mental illnesses with a definite diagnosis of the cause, including stroke (excluding lacunar infarctions), neurodegenerative diseases (such as parkinson's disease and alzheimer's disease). 5. co-occurring serious illnesses, such as malignant tumors, heart failure, respiratory failure, renal failure, severe liver dysfunction, severe blood system diseases, or gastrointestinal bleeding. 6. severe impairment in vision, hearing, language function, or limb muscular weakness that prevents completion of relevant tests. 7. women who are pregnant or breastfeeding. 8. mri scan contraindicated due to various reasons (such as claustrophobia). 9. any other reasons that prevent the collection of clinical data required for this study.
role of positron emission tomography in the evaluation of response to sorafenib in advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: positron emission tomography (pet) with \[18f\]fluorodeoxyglucose (fdg-pet) evaluates cancer cell glycolysis(warburg effect) as a surrogate for tumor response.the hypothesis of this study is that early changes in fdg-pet signal can predict sorafenib response in hepatocellular carcinoma (hcc).

hepatocellular carcinoma (hcc) is a major health issue worldwide, particularly in asia and africa, and a disease that has increased in incidence in the western world over the past 20 years primarily as a result of the prevalence of hepatitis c virus infection, which predisposes patients to hcc. sorafenib (a new oral potent multikinase inhibitor directed against both tumour proliferation and angiogenesis) can be considered standard of care for patients with advanced and metastatic hcc who are not candidates for curative or locoregional therapies. clinical benefit has been shown in 75% of patients with advanced hcc. pet is a noninvasive imaging technique which might be an effective tool for evaluating sorafenib treatment in hcc. the aim of this study is to evaluate this new treatment with pet with fluorodeoxyglucose (fdg), since the use of only computed tomography (ct) measurements can be questioned. our hypothesis is that early effects of sorafenib treatment in advanced hcc can be detected and quantified by pet-ct after one month of treatment. we try to reveal a decrease in tumour glucose uptake at one month and correlate it with other radiologic findings (measured by ct and diffusion-weighted nuclear resonance imaging) and the more clinically relevant endpoints clinical benefit and overall survival.

Eligibility criteria:
inclusion criteria: * advanced hepatocellular carcinoma: diagnostic assessment by biopsy/cytology; in cirrhotic patients conventional radiologic criteria are also accepted * more than 18 years of age. * life expectancy greater than three months * candidate to sorafenib therapy * informed consent required exclusion criteria: * hepatocellular carcinoma patients candidate to local/curative therapies(surgery/radiofrequency/tace/other local therapy * another active cancer than primary liver cancer

Keywords: positron emission tomography hepatocellular carcinoma liver cancer sorafenib response evaluation
pilot investigation to evaluate effectiveness of shockwave therapy, photobiomodulation and physical therapy in the management of non-insertional achilles tendinopathy

Conditions: Achilles Tendinopathy

Summary: this is a randomized control trial with an elective cross over after three months to evaluate three different treatments in the management of non-insertional achilles tendinopathy. the treatment methods include physical therapy, shockwave therapy and photobiomodulation.

this is a randomized control study with an elective cross over. in part 1 of the study participants will be randomized into one of three treatment arms: 1) physical therapy only; 2) physical therapy and shockwave therapy; 3) physical therapy, shockwave therapy and photobiomodulation. at 3 months, patients can choose to switch to a different treatment arm than they were initially randomized.

Eligibility criteria:
inclusion criteria: * a diagnosis of mid-portion achilles tendinopathy (including both unilateral and bilateral) * running is the pre-injury primary form of physical activity and pre-injury would complete on average 10 miles per week or more of running * visa-a \<80 at baseline to be eligible exclusion criteria * less than 3 months of symptoms * primary insertional achilles tendinopathy * diagnosis of rheumatological disease/connective tissue condition, symptomatic arthritis of foot and ankle, a primary running related injury outside achilles tendinopathy, other contraindications to pbmt or swt * have received swt within the past 3 months to their achilles * prior injection within 3 months * currently enrolled in pt for more than 4 weeks for their condition * women who are pregnant. * known history of achilles tendon tear * currently taking oral steroid or fluoroquinolone class of antibiotics
a comparison of the effect of two types of whole body vibration on fibromyalgia. a randomized controlled trial.

Conditions: Fibromyalgia

Summary: the objective of this study is to compare the effectiveness of two types of body vibration platform, one vertical and one rotational, through a 12-week training in patients with fibromyalgia.

this is a single blind randomized controlled trial. sixty patients of fm will be assigned randomly to 3 study groups: 20 patients will be part of the vertical whole body vibration experimental group in the eg1, that will perform a neuromuscular treatment using the vertical whole body vibration platform, another 20 will constitute the rotational whole body vibration experimental group in the eg2, that will perform a neuromuscular treatment using the rotational whole body vibration platform, and another 20 will constitute the control group (cg). all these subjects will sign the corresponding informed consent for their participation in the study, according to the ethical criteria established in the helsinki declaration. the study will take place between january and december 2016. three groups of variables were analyzed in the present study three times: before, after and follow-up after three months of the intervention.

Eligibility criteria:
inclusion criteria: -diagnosis of fibromyalgia according with the 1990 classification criteria of the american college of rheumatology for fibromyalgia exclusion criteria: * history of severe trauma. * severe disease that prevents supporting the program physical load. * pregnancy. * participation in a psychological or physical therapy program.
comparative study of antegrade versus retrograde cerebral perfusion in acute type a aortic dissection: a prospective study

Conditions: Acute Type A Aortic Dissection

Summary: this prospective study investigated the comparison of effectiveness of antegrade cerebral perfusion (acp) and retrograde cerebral perfusion (rcp) in providing cerebral protection during the surgical treatment of acute type a aortic dissection (taad). acute type a aortic dissection presents an aortic tear at its ascending portion, posing considerable risk with high morbidity and mortality incidence, especially from neurological insults. in total, 116 patients with acute type a aortic dissection were randomly assigned to undergo surgical intervention with either acp through axillary artery cannulation or rcp through superior vena cava cannula placed during deep hypothermic circulatory arrest. primary objectives focused on measuring and comparing the postoperative neurological complication rates associated with transient neurological deficits (tnd) and permanent neurological deficits (pnd). secondary outcomes of interest included the duration of mechanical ventilation, length of stay in the icu and hospital, and mortality.


Eligibility criteria:
inclusion criteria: - patients diagnosed with acute type a aortic dissection (taad). exclusion criteria: * hemodynamic instability. * known ischemic heart disease (ihd). * history of cerebrovascular stroke. * heart failure. * renal or hepatic impairment. * rheumatic heart disease. * previous history of radiotherapy.
an open, non-randomized pilot study on the effect of preservative free tafluprost (saflutan® augentropfen) in patients with ocular hypertension or primary open angle glaucoma with an uncontrolled intraocular pressure of 30 mmhg and more

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: increased intraocular pressure (iop) has been identified as the most important risk factor for the development and the progression of glaucoma. data from large interventional studies have shown that a decrease of iop is associated with a reduced risk of progression of the disease. this underlines the importance of a potent and save iop lowering therapy. the introduction of preservative free tafluprost offers a new treatment possibility using a potent topical prostaglandin analogue without the disadvantages of a co-administered preservative. the current study seeks to investigate the effect of an 8 week therapy with preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma having an iop of 30 mmhg or more.


Eligibility criteria:
inclusion criteria: * men and women aged over 18 years * diagnosed primary open angle glaucoma and an iop of 30mmhg or more in at least 1 eye at visit 1 at 8 am * patients with ocular hypertension as defined as an iop of 30mmhg or more and normal findings in the visual field and the optic nerve head exclusion criteria: * participation in a clinical trial in the 3 weeks before the screening visit * severe visual field loss as defined as an md of -15 or worse * symptoms of a clinically relevant illness in the 3 weeks before the first study day * presence or history of a severe medical condition that will interfere with the study aim as judged by the clinical investigator * presence or history of a severe ocular condition that will interfere with the study aim as judged by the clinical investigator * wearing of contact lenses * topical treatment with any ophthalmic drug in the 4 weeks preceding the study except glaucoma medication or topical lubricants * ocular infection * ocular surgery in the 6 months preceding the study * pregnancy, planned pregnancy or lactating * contraindication against the use of topical prostaglandin therapy

Keywords: primary open angle glaucoma ocular hypertension tafluprost saflutan intraocular pressure preservative free single dose unit
endoesophageal brachytherapy for patients with esophageal cancer

Conditions: Esophageal Cancer

Summary: depending upon the cancer stage, esophageal cancer can be treated with surgery, chemotherapy, radiation therapy, or a combination of these modalities. sometimes in addition to external radiation therapy or instead of external radiation therapy, select patients with esophageal cancer may benefit from localized radiation to the tumor, called esophageal brachytherapy. there are many different radiation techniques and delivery approaches for this type of specialized radiation therapy, and the purpose of this document is to provide a written summary of an innovative delivery method.

primary objective pilot study of multichannel endoesophageal brachytherapy applicator to determine dose distribution and conformality of a 6 channel balloon repositioning applicator. secondary objective(s) 1. to collect data in order to show how the 6-tube endoesophageal brachytherapy technique will be an improvement (more conformed dose distribution) over a previously designed 3-tube endoesophageal brachytherapy technique in patients who are candidates for esophageal brachytherapy 2. to evaluate acute toxicity of novel endoesophageal brachytherapy applicator. study design this innovative study will be an improvement over a previously designed 3-tube endoesophageal brachytherapy technique in patients who are candidates for esophageal brachytherapy. the brachytherapy planning process will utilize a novel multichannel balloon applicator. the initial treatment session will occur after the patient has been found to be eligible, the consent form has been completed, and the treatment plan has been created. the patient will undergo subsequent weekly treatments for 3 to 6 weeks after the initial treatment. the subject will be expected to participate in the trial throughout its entirety. the participation period is 6 months of which the patient will be evaluated and seen at months 3 and 6.

Eligibility criteria:
inclusion criteria: * biopsy-proved esophageal adenocarcinoma or squamous cell carcinoma * disease that can be encompassed in the radiotherapy treatment field * women of childbearing potential must practice adequate contraception * subjects must have the ability to understand and the willingness to sign a written informed consent document exclusion criteria: * concurrent chemotherapy at the time of brachytherapy treatments * tracheal or bronchial involvement * cervical esophagus location * stenosis that cannot be bypassed or dilated to allow for applicator placement * not willing or unable to provide informed consent * history of esophageal fistula

Keywords: brachytherapy multichannel balloon applicator
flortaucipir pet imaging in subjects with ftd

Conditions: Frontotemporal Dementia

Summary: this study is designed to assess the usefulness of flortaucipir in positron emission tomography (pet) imaging for subjects diagnosed with frontotemporal dementia (ftd).


Eligibility criteria:
inclusion criteria: * subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected frontotemporal dementia (ftd) pathology will be enrolled. clinical syndromes associated with ftd pathology include: behavioral-variant ftd, ftd with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome. * have provided informed consent or have a legally authorized (lar) provide consent for study procedures * have had volumetric brain mri obtained in site's companion protocol within one year of enrollment * can tolerate pet scan procedures exclusion criteria: * have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk * have history of risk factors for torsades de pointes (tdp) or taking medication known to cause qt prolongation * have history of drug or alcohol dependence within the last year * are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception * have history of relevant severe drug allergy or hypersensitivity * have received an investigational medication under fda ind protocol within 30 days of planned imaging session * have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session * possess pet scan evidence of amyloid deposition * determined by the investigator to be unsuitable for this type of study
glycemic index/ load and mental disorders

Conditions: Depression; Anxiety; Psychological Distress

Summary: a total of 300 adults would be included in the present cross-sectional study. glycemic index (gi) and glycemic load (gl) would be assessed by using a validated self-administered dish-based semi-quantitative food frequency questionnaire. validated iranian versions of hospital anxiety and depression scale and general health questionnaire-12 would be used to assess anxiety, depression and psychological distress.

frequency of 5 food groups will be asked in dish-based semi-quantitative food frequency questionnaire and they would be converted to grams. gi and gl will be estimated by using international table of gi and gl. validated iranian versions of hospital anxiety and depression scale and general health questionnaire (ghq)-12 were used to assess anxiety, depression and psychological distress. possible score range for anxiety and depression is from 0 to 21. scores of 8 or higher on either section were considered as the presence of anxiety or depression and scores of 7 or less were considered as normal status. in the present study, participants who got scores of 4 or more from ghq were considered to have psychological distress.

Eligibility criteria:
inclusion criteria: * men and women aged 18-75 years of free-living individuals. exclusion criteria: * over or underestimating of total energy intake * uncompleted questionnaire (more than 30% of questions)
establishment of social skills training group in adolescents with autism spectrum disorder and effectiveness analysis

Conditions: Autism Spectrum Disorder

Summary: autism spectrum disorders (asd) is a neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction across multiple contexts, and the presence of restricted, repetitive behavior and interests, affecting 1 in 68 children. although atypical social deficits onset in early childhood, their social relationships with peers may remain a challenge or even worsen for individuals with asd throughout the school years and beyond, as social contexts increase in complexity and pose higher social expectations.


Eligibility criteria:
inclusion criteria: * aged 11-20 years, currently enrolled in school between the sixth grade of elementary school and the third year of high school * with a clinical diagnosis of asd from a licensed mental health or medical professional based on dsm-5 * experiencing social difficulties as reported by parents in a structured intake interview * scored ≧ 26 on the caregiver-reported autism spectrum quotient (aq), indicating clinical impairment associated with asd * demonstrating verbal fluency in chinese * with a full-scale iq \> 70 on wais-iv * with motivation to participate in the intervention; * with a caregiver who was fluent in chinese and willing to participate as a social coach in the study. exclusion criteria: * a history of major mental illness (e.g., bipolar affective disorder, schizophrenia, or psychosis) or neurological diseases that might hinder participation in the treatment * visual impairment and/or hearing impairment that would preclude participation in group-based social activities.
electro physiological responses to kabat motor control re-education on bell's palsy: a randomized controlled study

Conditions: Facial Nerve Palsy; Bell's Palsy

Summary: to investigate the effect of kabat motor control re-education therapy on facial nerve electro physiological responses and facial muscles function in bell's palsy. background: facial nerve recovery in children could be improved through facilitation of nerve regeneration which can be enhanced through kabat motor control re-education therapy.

thirty children with bell's palsy will participate in this study. the patients will randomly be divided into two equal groups; the control group received the conventional selected program, and the study group received the same exercise training program in addition to kabat motor control re-education therapy. the program of treatment will be three times per week for six weeks. the evaluation methods: facial nerve distal latency, amplitude, and percentage of degenerations via the neuropack s1 meb9004 emg device, the facial disability index, and sunnybrook facial grading system (sbfgs) all the assessment methods before the program and after finishing the program

Eligibility criteria:
inclusion criteria: * thirty child diagnosed as acquired bell's palsy with unilateral peripheral facial paralysis * both gender * their age ranged from 12:16 years old. exclusion criteria: * difficulty to communicate or to understand program instructions * oral dentures, skin infection and metal implants on face * sensory loss over the face, recurrent facial paralysis * any other disorders or neurological deficits, * a history of surgical intervention for the ear and facial nerve palsy * pain of any other origin * non co-operative patients